Skip to content
sellModerate cluster of 510b5-1 plan

Marc Stapley sold $1.6M of VCYT

Chief Executive Officer at VERACYTE, INC.. 45,523 shares at an average of $35.97, traded Mar 4, 2026, filed Mar 6, 2026.

Warning score
50
Value
$1.6M
45,523 shares
Holdings after
357,554
-11% from before
From 52-week low
+57%
low $23.03, close $36.27
From 52-week high
-27%
high $49.38, as of Mar 4, 2026

Score components

  • Role
    CEO
    +25
  • Trade size
    $1.6M at market
    +25
  • Share of holdings sold
    Sold 11% of holdings
    +5
  • Cluster
    5 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -4.7%, 3m +44.0%, 6m +25.6%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

VCYTOct 12, 2026 · close 44.02
Since filing Mar 6, 2026: +30.0%SPY +16.6% · excess +13.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001539796-26-000010, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 4, 2026SOpen-market sale
Common Stock10b5-1
-19,244$35.56$684k383,833Mar 6, 2026
Mar 4, 2026SOpen-market sale
Common Stock10b5-1
-26,279$36.28$953k357,554Mar 6, 2026

Related signals

Other insiders at VERACYTE, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
14Weak
VCYTsell 210b5-1
VERACYTE, INC.
John Leite
Global Chief Commercial Off
$161k
4,015 shares
-3%
27Weak
VCYTsell 610b5-1
VERACYTE, INC.
Jens Holstein
director
$205k
5,000 shares
-15%
28Weak
VCYTsell 510b5-1
VERACYTE, INC.
Rebecca Chambers
Chief Financial Officer
$157k
3,652 shares
-2%
29Weak
VCYTsell 510b5-1
VERACYTE, INC.
Phillip G. Febbo
Chief Scientific & Med Officer
$564k
13,110 shares
-9%
21Weak
VCYTsell 510b5-1
VERACYTE, INC.
Annie McGuire
EVP, General Counsel
$140k
3,254 shares
-2%
19Weak
VCYTsell 510b5-1
VERACYTE, INC.
Muna Bhanji
director
$80k
1,864 shares
-4%
27Weak
VCYTsell 510b5-1
VERACYTE, INC.
Karin Eastham
director
$197k
3,729 shares
-20%
29Weak
VCYTsell 610b5-1
VERACYTE, INC.
Rebecca Chambers
Chief Financial Officer
$177k
3,561 shares
-2%
31Weak
VCYTsell 610b5-1
VERACYTE, INC.
John Leite
Global Chief Commercial Off
$700k
13,975 shares
-10%
21Weak
VCYTsell 610b5-1
VERACYTE, INC.
Annie McGuire
EVP, General Counsel
$158k
3,176 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Marc Stapley sold $1.6M of VCYT | InsiderTell